Transient citalopram-induced auditory hallucinations in a patient with Parkinson's disease and depression

Australian and New Zealand Journal of Psychiatry

Volumn 46, Issue 2, 2012, Pages 178-

  Wand, Anne P ^a,b  

^a Sydney Local Health Network   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CITALOPRAM; ANTIDEPRESSANT AGENT;

AUDITORY HALLUCINATION; BONE METASTASIS; CELLULITIS; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; GASTROESOPHAGEAL REFLUX; HUMAN; INSOMNIA; LETTER; MAJOR DEPRESSION; NAUSEA; PARKINSON DISEASE; PROSTATE CANCER; SUICIDE ATTEMPT; AGED; CASE REPORT; CHEMICALLY INDUCED DISORDER; HALLUCINATION; MALE;

AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; HALLUCINATIONS; HUMANS; MALE; PARKINSON DISEASE;

EID: 84861705839     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867411433221     Document Type: Letter

References (5)

1. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000 ; 123: 733-745
2. Rabey JM, Orlov E, Korczyn AD. Comparison of fluvoxamine versus amitriptyline for treatment of depression in Parkinson's disease. Neurology. 1996 ; 46: A374
3. Reijnders JS, Ehrt U, Weber WEJ, et al. A systematic review of prevalence studies of depression in Parkinson's Disease. Movement Disorders. 2008 ; 23: 183-189
4. Skapinakis P, Bakola E, Salanti G, et al. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomised controlled trials. BMC Neurology. 2010 ; 10: 49
5. Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with citalopram. A placebo controlled trial. Nordic Journal of Psychiatry. 1998 ; 52: 163-169